# Phase 3 Urinary Bladder cancer trials recruiting: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 3 for Urinary Bladder cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Urinary Bladder cancer trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/urinary-bladder-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07914101 | Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer | Assiut University | Phase 3 | Not yet recruiting | Bladder Cancer, TURBT, Radiotherapy | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914101) |
| October 13, 2026 | NCT07869836 | BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial... | SystImmune Inc. | Phase 3 | Recruiting | Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Bladder Cancer (BC), Bladder (Urothelial, Transitional... | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869836) |
| September 21, 2026 | NCT07829783 | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Bladder Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829783) |
| September 4, 2026 | NCT07804056 | A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade... | Hamlet Pharma AB | Phase 3 | Recruiting | Urinary Bladder Neoplasms, Non-muscle Invasive Bladder Cancer (NMIBC) | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804056) |
| August 31, 2026 | NCT07795255 | Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort) | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Bladder (Urothelial, Transitional Cell) Cancer, Hematuria | 1,740 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795255) |
| July 22, 2026 | NCT07720284 | An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC | AstraZeneca | Phase 3 | Recruiting | High-risk Muscle Invasive Urothelial Carcinoma | 915 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07720284) |
| May 4, 2026 | NCT07566156 | Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer... | Astellas Pharma Global Development, Inc. | Phase 3 | Recruiting | Urothelial Cancer, Urinary Bladder Neoplasms | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566156) |
| March 18, 2026 | NCT07480356 | Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With... | Protara Therapeutics | Phase 3 | Recruiting | Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder... | 284 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480356) |
| March 11, 2026 | NCT07464145 | A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer | Relmada Therapeutics, Inc. | Phase 3 | Not yet recruiting | Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial... | 393 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464145) |
| February 19, 2026 | NCT07419295 | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Bladder Cancer | 590 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419295) |
| October 20, 2025 | NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Eli Lilly and Company | Phase 3 | Recruiting | Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218380) |
| July 31, 2025 | NCT07097142 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for... | NRG Oncology | Phase 3 | Recruiting | Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 | 486 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07097142) |
| July 16, 2025 | NCT07067749 | Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer | University of Rome Tor Vergata | Phase 3 | Recruiting | Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Requiring Cystectomy, Bladder Carcinoma, Bladder... | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07067749) |
| May 31, 2025 | NCT07000084 | Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer... | Alliance for Clinical Trials in Oncology | Phase 3 | Recruiting | Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8 | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07000084) |
| November 25, 2024 | NCT06703476 | A Study of Surgical Techniques During Cystectomy | Memorial Sloan Kettering Cancer Center | Phase 3 | Recruiting | Bladder Cancer | 530 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06703476) |
| July 29, 2024 | NCT06525571 | Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection | Johns Hopkins University | Phase 3 | Recruiting | Bladder Cancer | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06525571) |
| June 4, 2024 | NCT06441110 | Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and... | Fujian Medical University Union Hospital | Phase 3 | Recruiting | Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active, Multicenter Study, Treatment Outcome, Neoplasm... | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06441110) |
| April 15, 2024 | NCT06364904 | A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without... | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | Not yet recruiting | Bladder Cancer | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06364904) |
| April 12, 2023 | NCT05810623 | Single-Dose Intravesical Chemotherapy After Diagnostic URS | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Upper Urinary Tract Urothelial Carcinoma, Bladder Cancer | 394 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05810623) |
| February 14, 2023 | NCT05726786 | The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial) | Centre Hospitalier Universitaire Vaudois | Phase 3 | Recruiting | Bladder Cancer, Interstitial Cystitis, Painful Bladder Syndrome, Neurogenic Bladder, Hemorrhagic Cystitis... | 232 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05726786) |
| September 8, 2021 | NCT05037279 | Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) | Verity Pharmaceuticals Inc. | Phase 3 | Recruiting | Bladder Cancer, Bladder Cancer Recurrent, Neoplasm Recurrence, Urothelial Carcinoma Bladder, Urothelial Carcinoma... | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05037279) |
| October 5, 2020 | NCT04574960 | Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) | University Health Network, Toronto | Phase 3 | Recruiting | Bladder Cancer, Bladder Urothelial Carcinoma | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04574960) |
| July 13, 2017 | NCT03216525 | Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol | Brigham and Women's Hospital | Phase 3 | Recruiting | Bladder Cancer | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03216525) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| NRG Oncology | 1 |
| Protara Therapeutics | 1 |
| University Health Network, Toronto | 1 |
| Centre Hospitalier Universitaire Vaudois | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| SystImmune Inc. | 1 |
| Verity Pharmaceuticals Inc. | 1 |
| Relmada Therapeutics, Inc. | 1 |
| [Astellas Pharma Global Development, Inc.](https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc) | 1 |
| Fujian Medical University Union Hospital | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| University of Rome Tor Vergata | 1 |
| Brigham and Women's Hospital | 1 |
| Johns Hopkins University | 1 |
| Hamlet Pharma AB | 1 |
| Assiut University | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 12 |
| Canada | 7 |
| China | 5 |
| Italy | 4 |
| Taiwan | 4 |
| Australia | 3 |
| Brazil | 3 |
| France | 3 |
| Germany | 3 |
| Japan | 3 |
| South Korea | 3 |
| Spain | 3 |
| United Kingdom | 3 |
| Czechia | 2 |
| Netherlands | 2 |
| Poland | 2 |
| Ukraine | 2 |
| Denmark | 1 |
| Hungary | 1 |
| Turkey (Türkiye) | 1 |
| Austria | 1 |
| Argentina | 1 |
| Belgium | 1 |
| Greece | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Naturopathic clinics in the United States](https://specstream.ai/data/businesses/naturopathic-clinics/united-states)
- [Tools wholesalers in the United States](https://specstream.ai/data/businesses/tools-wholesalers/united-states)
- [Carpet installation companies in the United States](https://specstream.ai/data/businesses/carpet-installation-companies/united-states)
- [Honduran restaurants in the United States](https://specstream.ai/data/businesses/honduran-restaurants/united-states)
- [Private investigators in the United States](https://specstream.ai/data/businesses/private-investigators/united-states)
- [Aircraft service companies in the United States](https://specstream.ai/data/businesses/aircraft-service-companies/united-states)
